Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three …

PA Ascierto, M Mandalà, PF Ferrucci… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Limited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is …
被引用次数：132 相关文章

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three …

PA Ascierto, M Mandalà, PF Ferrucci… - Journal of Clinical …, 2022 - europepmc.org
Purpose Limited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. Methods SECOMBIT is a …

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three …

PA Ascierto, M Mandalà, PF Ferrucci… - Journal of Clinical …, 2023 - zora.uzh.ch
Purpose: Limited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. Methods: SECOMBIT is a …

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three …

PA Ascierto, M Mandala, PF Ferrucci… - JOURNAL OF …, 2023 - research.unipg.it
PURPOSELimited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODSSECOMBIT is …

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three …

PA Ascierto, M Mandalà, PF Ferrucci… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE Limited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is …

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three …

P Ascierto, M Mandalà, P Ferrucci… - JOURNAL OF …, 2023 - sfera.unife.it
PURPOSELimited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODSSECOMBIT is …

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three …

PA Ascierto, M Mandalà, PF Ferrucci… - Journal of clinical …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose Limited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. Methods SECOMBIT is a …